

FORWARDHEALTH
**PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR CYTOKINE AND CELL
ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR RHEUMATOID ARTHRITIS (RA),
JUVENILE IDIOPATHIC ARTHRITIS (JIA), AND PSORIATIC ARTHRITIS
COMPLETION INSTRUCTIONS**

ForwardHealth requires certain information to enable the programs to authorize and pay for medical services provided to eligible members.

Members of ForwardHealth programs are required to give providers full, correct, and truthful information for the submission of correct and complete claims for reimbursement. Per Wis. Admin. Code § DHS 104.02(4), this information should include, but is not limited to, information concerning enrollment status, accurate name, address, and member ID number.

Under Wis. Stat. § 49.45(4), personally identifiable information about program applicants and members is confidential and is only used for purposes directly related to ForwardHealth administration, such as determining eligibility of the applicant, processing prior authorization (PA) requests, or processing provider claims for reimbursement. Failure to supply the information requested by the form may result in denial of PA or payment for the services.

The use of this form is mandatory when requesting PA for certain drugs. Refer to the applicable service-specific publications for service restrictions and additional documentation requirements. Provide enough information for ForwardHealth to make a determination about the request. Prescribers and pharmacy providers are required to retain a completed copy of the form.

INSTRUCTIONS

Prescribers are required to complete and sign the Prior Authorization/Preferred Drug List (PA/PDL) for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), and Psoriatic Arthritis, F-01951. Pharmacy providers are required to use the PA/PDL for Cytokine and CAM Antagonist Drugs for RA, JIA, and Psoriatic Arthritis form to request PA using the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or by submitting a PA request on the ForwardHealth Portal or on paper. Prescribers and pharmacy providers are required to retain a completed copy of the form.

Providers may submit PA requests on a PA/PDL form in one of the following ways:

- 1) For STAT-PA requests, pharmacy providers should call 800-947-1197.
- 2) For requests submitted on the ForwardHealth Portal, providers may access www.forwardhealth.wi.gov/.
- 3) For paper PA requests by fax, pharmacy providers should submit a Prior Authorization Request Form (PA/RF), F-11018, and the appropriate PA/PDL form to ForwardHealth at 608-221-8616.
- 4) For paper PA requests by mail, pharmacy providers should submit a PA/RF and the appropriate PA/PDL form to the following address:

ForwardHealth
Prior Authorization
Ste 88
313 Blettner Blvd
Madison WI 53784

Providers should make duplicate copies of all paper documents mailed to ForwardHealth. The provision of services that are greater than or significantly different from those authorized may result in nonpayment of the billing claim(s).

SECTION I – MEMBER INFORMATION

Element 1 – Name – Member

Enter the member's last name, first name, and middle initial. Use Wisconsin's Enrollment Verification System (EVS) to obtain the correct spelling of the member's name. If the name or spelling of the name on the ForwardHealth identification card and the EVS do not match, use the spelling from the EVS.

Element 2 – Member Identification Number

Enter the member ID. Do not enter any other numbers or letters. Use the ForwardHealth card or the EVS to obtain the correct member ID.

Element 3 – Date of Birth – Member

Enter the member's date of birth in MM/DD/CCYY format.

PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR RHEUMATOID ARTHRITIS (RA), JUVENILE IDIOPATHIC ARTHRITIS (JIA), AND PSORIATIC ARTHRITIS COMPLETION INSTRUCTIONS

F-01951A (01/2017)

SECTION II – PRESCRIPTION INFORMATION

If this section is completed, providers do not need to include a copy of the prescription documentation used to dispense the product requested.

Element 4 – Drug Name

Enter the drug name.

Element 5 – Drug Strength

Enter the strength of the drug listed in Element 4.

Element 6 – Date Prescription Written

Enter the date the prescription was written.

Element 7 – Directions for Use

Enter the directions for use of the drug.

Element 8 – Name – Prescriber

Enter the name of the prescriber.

Element 9 – National Provider Identifier (NPI) – Prescriber

Enter the 10-digit National Provider Identifier (NPI) of the prescriber.

Element 10 – Address – Prescriber

Enter the complete address of the prescriber's practice location, including the street, city, state, and ZIP+4 code.

Element 11 – Telephone Number – Prescriber

Enter the telephone number, including the area code, of the office, clinic, facility, or place of business of the prescriber.

SECTION III – CLINICAL INFORMATION FOR RA, JIA, AND PSORIATIC ARTHRITIS

Include diagnostic and clinical information explaining the need for the product requested. Complete all elements in Section III. Check "yes" or "no" as it applies to each question. Include written documentation as indicated.

Element 12 – Diagnosis Code and Description

Enter the appropriate and most-specific *International Classification of Diseases* (ICD) diagnosis code and description most relevant to the drug requested. The ICD diagnosis code must correspond with the ICD description.

Element 13

Check the appropriate box(es) to identify whether the member has one of the following conditions:

- Juvenile idiopathic arthritis
- Rheumatoid arthritis
- Psoriatic arthritis without axial symptoms
- Psoriatic arthritis with axial symptoms

Element 14

Check the appropriate box to indicate whether or not the prescription was written by a rheumatologist or through a rheumatology consultation.

Element 15

Check the appropriate box to indicate whether or not the member is currently using the requested cytokine and CAM antagonist drug. If yes, indicate the approximate date that therapy was started.

Element 16

Check the appropriate box next to the drugs listed that the member has taken for at least **three** consecutive months and experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse drug reaction. Indicate the dose, dates taken, and reason for discontinuation.

Check "none" if appropriate, and indicate the reason the member is unable to use the drugs listed.

Note: If none, a copy of the member's medical records must be submitted with the PA request to support the condition being treated, details regarding previous medication use, and outline the member's current treatment plan.

PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR RHEUMATOID ARTHRITIS (RA), JUVENILE IDOPATHIC ARTHRITIS (JIA), AND PSORIATIC ARTHRITIS COMPLETION INSTRUCTIONS

F-01951A (01/2017)

Element 17

Check the appropriate box to indicate whether or not the member has attempted other drug therapies for RA, JIA, or psoriatic arthritis (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs], cyclooxygenase [COX-2] inhibitors, glucocorticoids, or IV immunomodulators such as infliximab). If yes, indicate the drug names, dose, specific details about the treatment response, and the approximate dates each drug was taken in the space provided. If additional space is needed, continue documentation in Section VI of the form.

SECTION III A – ADDITIONAL CLINICAL INFORMATION FOR NON-PREFERRED CYTOKINE AND CAM ANTAGONST DRUG REQUESTS

Note: Prior authorization requests for non-preferred cytokine and CAM antagonist drugs must be submitted on paper.

Element 18

Indicate the cytokine and CAM antagonist drugs the member has taken, dose, dates taken, and specific details regarding the treatment response. If additional space is needed, continue documentation in Section VI of the form.

Note: A copy of the member’s medical records must be submitted with the PA request to support the condition being treated, details regarding previous medication use, and outline the member’s current treatment plan.

SECTION III B – ADDITIONAL CLINICAL INFORMATION FOR SIMPONI REQUESTS

Element 19

Check the appropriate box to indicate whether or not the member will continue to take methotrexate in combination with Simponi.

SECTION IV – AUTHORIZED SIGNATURE

Element 20 – Signature – Prescriber

The prescriber is required to complete and sign this form.

Element 21 – Date Signed

Enter the month, day, and year the form was signed in MM/DD/CCYY format.

SECTION V – FOR PHARMACY PROVIDERS USING STAT-PA

Element 22 – National Drug Code

Enter the appropriate 11-digit National Drug Code for each drug.

Element 23 – Days’ Supply Requested

Enter the requested days’ supply.

Element 24 – NPI

Enter the NPI. Also enter the taxonomy code if the pharmacy provider’s taxonomy code is not 333600000X.

Element 25 – Date of Service

Enter the requested first date of service (DOS) for the drug in MM/DD/CCYY format. For STAT-PA requests, the DOS may be up to 31 days in the future or up to 14 days in the past.

Element 26 – Place of Service

Enter the appropriate place of service code designating where the requested item would be provided/performed/dispensed.

Code	Description
01	Pharmacy
13	Assisted living facility
14	Group home
32	Nursing facility
34	Hospice
50	Federally qualified health center
65	End-stage renal disease treatment facility
72	Rural health clinic

Element 27 – Assigned PA Number

Enter the PA number assigned by the STAT-PA system.

Element 28 – Grant Date

Enter the date the PA request was approved by the STAT-PA system.

PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR RHEUMATOID ARTHRITIS (RA), JUVENILE IDOPATHIC ARTHRITIS (JIA), AND PSORIATIC ARTHRITIS COMPLETION INSTRUCTIONS

4 of 4

F-01951A (01/2017)

Element 29 – Expiration Date

Enter the date the PA expires as assigned by the STAT-PA system.

Element 30 – Number of Days Approved

Enter the number of days for which the PA request was approved by the STAT-PA system.

SECTION VI – ADDITIONAL INFORMATION

Element 31

Include any additional information in the space provided. Additional diagnostic and clinical information explaining the need for the product requested may be included here.